ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0999

Differences in Chromatin Accessibility Pre- and Post-Induction Therapy in Pediatric Lupus
Abstract Number: 1383

Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity
Abstract Number: 0377

Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Abstract Number: 1847

Differences in Key Patient-reported Outcome Domains Identified by the Patient Acceptable Symptom State in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study)
Abstract Number: 0206

Differences in Medicinal Cannabis Use According to Demography, Rationale, and Patient-Physician Interactions Between the United States and Canada
Abstract Number: 0844

Differences in Skin Advanced Glycation End-Products Levels Between Subgroups of Achilles Tendinopathy
Abstract Number: 1415

Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study
Abstract Number: 1763

Different Humoral but Similar Cellular Responses of Patients with Autoimmune Inflammatory Rheumatic Diseases Under Disease-modifying Anti-rheumatic Drugs After COVID-19 Vaccination
Abstract Number: 0015

Differential Antigen Binding of Closely Related Monoclonal ACPA
Abstract Number: 0068

Differential Diagnostic Coding Patterns and Associated Sociodemographic Factors in Childhood-Onset Lupus Nephritis
Abstract Number: 0668

Differential Expression of Interferon Related Genes in SLE Patients of Asian and European Ancestries Abstract
Abstract Number: 1158

Differential Plasma Levels of S100 Proteins in Male versus Female Patients with Ankylosing Spondylitis
Abstract Number: 1039

Differential Retention of Adalimumab and Etanercept Biosimilars Compared to Originator Treatments: Results of a Retrospective French Multicentre Study
Abstract Number: 1153

Differentially Expressed Genes in Males and Females with Ankylosing Spondylitis (AS): Transcriptomics of IL-17-producing Cells in Patients with AS
Abstract Number: 1666

Differentiation of Injury-associated Macrophages in Lupus Kidneys Is Conserved in Humans and Lupus Mouse Models

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].